From Young to Old: Mimicking Neuronal Aging in Directly Converted Neurons from Young Donors.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 27 06 2024
revised: 23 07 2024
accepted: 24 07 2024
medline: 9 8 2024
pubmed: 9 8 2024
entrez: 9 8 2024
Statut: epublish

Résumé

A substantial challenge in human brain aging is to find a suitable model to mimic neuronal aging in vitro as accurately as possible. Using directly converted neurons (iNs) from human fibroblasts is considered a promising tool in human aging since it retains the aging-associated mitochondrial donor signature. Still, using iNs from aged donors can pose certain restrictions due to their lower reprogramming and conversion efficacy than those from younger individuals. To overcome these limitations, our study aimed to establish an in vitro neuronal aging model mirroring features of in vivo aging by acute exposure on young iNs to either human stress hormone cortisol or the mitochondrial stressor rotenone, considering stress as a trigger of in vivo aging. The impact of rotenone was evident in mitochondrial bioenergetic properties by showing aging-associated deficits in mitochondrial respiration, cellular ATP, and MMP and a rise in glycolysis, mitochondrial superoxide, and mitochondrial ROS; meanwhile, cortisol only partially induced an aging-associated mitochondrial dysfunction. To replicate the in vivo aging-associated mitochondrial dysfunctions, using rotenone, a mitochondrial complex I inhibitor, proved to be superior to the cortisol model. This work is the first to use stress on young iNs to recreate aging-related mitochondrial impairments.

Identifiants

pubmed: 39120291
pii: cells13151260
doi: 10.3390/cells13151260
pii:
doi:

Substances chimiques

Rotenone 03L9OT429T
Hydrocortisone WI4X0X7BPJ
Reactive Oxygen Species 0
Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Swiss National Science Foundation
ID : 31003A-179294
Pays : Switzerland
Organisme : Novartis Foundation
ID : 18C143
Organisme : European Union's Seventh Framework Programme
ID : FP7/2007-2013
Organisme : Innovative Medicines Initiative Joint Undertaking
ID : 115439
Organisme : EFPIA companies

Auteurs

Nimmy Varghese (N)

Research Cluster Molecular and Cognitive Neurosciences, University of Basel, 4002 Basel, Switzerland.
Neurobiology Lab for Brain Aging and Mental Health, University Psychiatric Clinics Basel, 4002 Basel, Switzerland.

Amandine Grimm (A)

Research Cluster Molecular and Cognitive Neurosciences, University of Basel, 4002 Basel, Switzerland.
Neurobiology Lab for Brain Aging and Mental Health, University Psychiatric Clinics Basel, 4002 Basel, Switzerland.
Department of Biomedicine, University of Basel, 4055 Basel, Switzerland.

M Zameel Cader (MZ)

Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford OX3 9DS, UK.

Anne Eckert (A)

Research Cluster Molecular and Cognitive Neurosciences, University of Basel, 4002 Basel, Switzerland.
Neurobiology Lab for Brain Aging and Mental Health, University Psychiatric Clinics Basel, 4002 Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH